Blood poisoning sepsis
Conditions
Interventions
Subjects will receive dipyridamole (five day treatment with 200 mg twice daily
n=15) or placebo (n=15). The day of the experiment, prehydration will be
performed by infusion of 1.5 L 2.5% glucose/0.
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Age >= 18 and
Exclusion criteria
Exclusion criteria: Use of any medication. History of allergic reaction to dipyridamole Bleeding disorder. Smoking. Previous spontaneous vagal collapse. History, signs or symptoms of cardiovascular disease. Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrioventricular block or a complex bundle branch block. Hypertension (defined as RR systolic > 160 or RR diastolic > 90). Hypotension (defined as RR systolic 120 µmol/l). Liver enzyme abnormalities or positive hepatitis serology. Positive HIV serology or any other obvious disease associated with immune deficiency. Febrile illness in the week before the LPS challenge. Participation in a drug trial or donation of blood 3 months prior to the LPS challenge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameter is the concentration of circulating cytokines following LPS administration in the absence or presence of dipyridamole. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study parameters include endothelial dysfunction, vascular reactivity, subclinical renal injury and the endogenous adenosine concentration after LPS administration in the absence or presence of dipyridamole. | — |
Countries
Netherlands
Outcome results
None listed